Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease

BACKGROUND: Dimebon is a retired non-selective antihistamine drug currently being investigated as a therapeutic agent for the treatment of Alzheimer's disease (AD). Results from several completed clinical trials are mixed and contradictory. Proper interpretations of these clinical observations,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Ferruzzi, Mario G, Varghese, Merina, Qian, Xianjuan, Cheng, Alice, Xie, Mathew, Zhao, Wei, Ho, Lap, Pasinetti, Giulio M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035024/
https://www.ncbi.nlm.nih.gov/pubmed/21247479
http://dx.doi.org/10.1186/1750-1326-6-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035024/
https://www.ncbi.nlm.nih.gov/pubmed/21247479
http://dx.doi.org/10.1186/1750-1326-6-7

Ejemplares similares